Article Details
Retrieved on: 2024-11-25 17:33:34
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Intellia Therapeutics' CRISPR-based therapy, NTLA-2001, targeting protein misfolding in hereditary transthyretin amyloidosis. The therapy's RMAT designation emphasizes its potential impact on neurological disorders and pharmaceuticals, showcasing innovative treatment strategies.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here